Xenetic Biosciences (XBIO) Announces Favorable Data from Third Cohort of ErepoXen Phase 3 in Anemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Dow up on UnitedHealth boost; higher bond yields, Mideast tensions cap gains
- UnitedHealth (UNH) beats earnings, revenue estimates in Q1; shares up
- BofA profit drops as provisions rise, but beats estimates on investment banking surge
- Morgan Stanley (MS) earnings beat lifts stock
- Johnson & Johnson (JNJ) posts mixed results, narrows full-year guidance
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- GE HealthCare (GEHC) Announces Resignation of Jan Makela, CEO of Imaging
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia
October 10, 2016 7:35 AM EDTHemoglobin Levels Showed Increase Over Cohort 2 and Maintained Therapeutic Range
ErepoXen Generally Well Tolerated with No Antigenic Response
Study PK Results Confirm Serum Half Life
LEXINGTON, Mass.--(BUSINESS WIRE)-- Xenetic Biosciences, Inc. (OTCQB: XBIO) (Xenetic or the Company), a biopharmaceutical company developing next-generation biologic drugs and... More
